Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

The subject-matter of the invention is a process for encapsulating one or more substances with a matrix, wherein said process comprises the preparation of a mixture of said matrix in the liquid state with said substance(s), then the solidification of the mixture obtained, said matrix consisting of vanillin or ethylvanillin or a vanillin/ethylvanillin mixture. The solid compound thus obtained is particularly advantageous in the field of food for human consumption and animal feed, in the pharmaceutical field, as a fragrance in the cosmetics, perfumery and detergence field, or as an encapsulated active ingredient in the pharmaceutical field. The use of a compound chosen form vanillin, ethylvanillin and vanillin/ethylvanillin mixtures as encapsulating agent is also subject-matter of the present invention.

Solid lipid nanoparticles (SLNs) and suspensions thereof in an aqueous phase are provided, in which the SLNs have high content of oil-soluble pigment and high stability. A food product, such as a beverage, comprising said SLNs is also provided.

The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

An inhalable microparticles having cysteamine hyaluronate salt is provided. Also a preparation method and a pharmaceutical composition thereof are provided.

An oral solid formulation includes irinotecan or a pharmaceutically acceptable salt thereof as an active ingredient, and an acidifying agent.

The present invention relates to topical compositions comprising at least 10.sup.6 CFU/g probiotic bacteria that remain viable in said composition for at least 6 months at 25° C./60% RH. The present invention also relates to methods for preparing such topical compositions, and a device suitable for long-term storage of viable probiotic bacteria. In addition, the present invention relates to the use of said composition.

This invention relates to high drug load compositions of medium chain triglycerides (MCT), and to methods for treatment with such compositions at amounts effective to elevate ketone body concentrations so as to treat conditions associated with reduced neuronal metabolism, for example Alzheimer's disease.

The present invention provides certain lipo-glycopeptide cleavable derivatives and methods for using the same for the treatment of bacterial infections, for example, pulmonary bacterial infections. The LGPC derivatives include a cleavable moiety that in certain embodiments, is designed to allow for cellular uptake and/or a more rapid clearance of the glycopeptide metabolite (i.e., the cleaved glycopeptide) from the site of administration (e.g., the lung) as compared to the uncleaved LGPC.

Provided is a composition comprising delamanid particles for which the formation of secondary particles is suppressed. Specifically, provided is a composition comprising (A) delamanid particles and (B) a surface stabilizer.